Background: Soluble mesothelin-related peptide (SMRP) is a promising diagnostic biomarker for malignant pleural mesothelioma (MPM), but various confounders hinder its usefulness in surveillance programmes. We previously showed that a single nucleotide polymorphism (SNP) within the 3'untranslated region (3'UTR) of the () gene could affect the levels of SMRP.

Objectives: To focus on SNPs located within promoter as possible critical genetic variables in determining SMRP levels.

Methods: The association between SMRP and SNPs was tested in 689 non-MPM subjects and 70 patients with MPM. Reporter plasmids carrying the four most common haplotypes were compared in a dual luciferase assay, and in silico analyses were performed to investigate the putative biological role of the SNPs.

Results: We found a strong association between serum SMRP and variant alleles of rs3764247, rs3764246 (in strong linkage disequilibrium with rs2235504) and rs2235503 in non-MPM subjects. Inclusion of the genotype information led to an increase in SMRP specificity from 79.9% to 85.5%. Although not statistically significant, the group with MPM showed the same trend of association. According to the in vitro luciferase study, rs3764247 itself had a functional role. In silico approaches showed that the binding sites for transcription factors such as Staf and ZNF143 could be affected by this SNP. The other SNPs were shown to interact with each other in a more complex way.

Conclusions: These data support the suggestion that SMRP performance is affected by individual (ie, genetic) variables and that expression is influenced by SNPs located within the promoter regulatory region.

Download full-text PDF

Source
http://dx.doi.org/10.1136/oemed-2016-104024DOI Listing

Publication Analysis

Top Keywords

soluble mesothelin-related
8
mesothelin-related peptide
8
snps located
8
located promoter
8
genetic variables
8
non-mpm subjects
8
smrp
6
mesothelin promoter
4
promoter variants
4
variants associated
4

Similar Publications

Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy.

J Thorac Cardiovasc Surg

October 2024

Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Division of Hemato-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex; David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address:

Article Synopsis
  • Immune checkpoint therapy (ICT) has changed the treatment landscape for malignant pleural mesothelioma (MPM), but nearly half of patients do not see benefits, emphasizing the need for predictive biomarkers.
  • This study evaluated the prognostic value of serum soluble mesothelin-related peptide (SMRP) and PD-L1 levels in 125 MPM patients undergoing ICT, using statistical analyses to determine their impact on overall survival (OS).
  • Results showed that higher pre-ICT SMRP levels are linked to poorer prognosis, with low levels indicating better survival outcomes, suggesting that SMRP could serve as a valuable biomarker for future MPM treatment studies.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied lung disease linked to autoimmune diseases and wanted to find helpful tests to diagnose it!
  • They looked at 3,169 patients and measured specific substances in their blood, focusing on two types of lung disease!
  • The study found that a substance called KL-6 was really useful for diagnosing lung disease, and using both blood tests and patient info could help doctors make better decisions!
View Article and Find Full Text PDF

Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.

Thorac Cancer

May 2024

The Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (http://www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham, and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Background: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers for monitoring PM. We prospectively studied the utility of these biomarkers after pleurectomy decortication (PD).

View Article and Find Full Text PDF

Exposure to asbestiform fibers, including chrysotile and amphibole, is carcinogenic, causing malignant pleural mesothelioma (MPM) when inhaled. Some populations globally face Naturally Occurring Asbestos (NOA) exposure, leading to MPM cases like in Biancavilla, Italy, from Fluoro-edenite (FE) contamination. Studies show NOA exposure causes epigenetic changes, focusing on mesothelin methylation, an MPM marker, and altered inflammation, emphasizing the health risks of FE and asbestos.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!